Q1 FY27 delivered 13% revenue and 14.5% PAT growth year-over-year, with strong DBF segment momentum and leadership in GLP-1 and insulin market share. EBITDA margin compressed slightly, while priorities focus on therapy momentum, new launches, and capacity expansion.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.